Published in J Exp Med on September 21, 1998
A critical analysis of current in vitro and in vivo angiogenesis assays. Int J Exp Pathol (2009) 2.24
Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res (2005) 2.11
The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol (2011) 1.82
Gene expression and angiotropism in primary CNS lymphoma. Blood (2006) 1.79
Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev (2009) 1.68
IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury. J Clin Invest (2000) 1.66
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res (2010) 1.58
Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J Exp Med (1999) 1.55
Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol (2003) 1.55
Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis (2003) 1.49
IL-4 in the brain: a cytokine to remember. J Immunol (2012) 1.34
Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med (2003) 1.28
Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev (2011) 1.28
Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions. Cell Cycle (2010) 1.22
Regulation of inflammation by interleukin-4: a review of "alternatives". J Leukoc Biol (2012) 1.20
Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res (2007) 1.20
Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS One (2008) 1.14
Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer (2006) 1.09
Tumor angiogenesis: insights and innovations. J Oncol (2010) 1.04
Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res (2009) 0.98
The angiogenic response of the aorta to injury and inflammatory cytokines requires macrophages. J Immunol (2008) 0.96
Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem (2010) 0.95
Effect of interleukin-4 on vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Clin Exp Immunol (2007) 0.93
Tumor rejection by modulation of tumor stromal fibroblasts. J Exp Med (2003) 0.91
Effects of endostatin-vascular endothelial growth inhibitor chimeric recombinant adenoviruses on antiangiogenesis. World J Gastroenterol (2004) 0.90
Eosinophils and oral squamous cell carcinoma: a short review. J Oncol (2009) 0.90
Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs (1999) 0.88
Splice isoforms of human interleukin-4 are functionally active in mice in vivo. Immunology (2011) 0.86
Interleukin-4 rapidly inhibits calcium transients in response to carbachol in bovine airway smooth muscle cells. Am J Respir Cell Mol Biol (2001) 0.84
Interleukin-4 and melatonin ameliorate high glucose and interleukin-1β stimulated inflammatory reaction in human retinal endothelial cells and retinal pigment epithelial cells. Mol Vis (2014) 0.84
The influence of interleukin-4 on ligament healing. Wound Repair Regen (2011) 0.83
Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptide. Ann Rheum Dis (2012) 0.81
Suppression of ongoing experimental allergic encephalomyelitis (EAE) in Lewis rats: synergistic effects of myelin basic protein (MBP) peptide 68-86 and IL-4. Clin Exp Immunol (2000) 0.80
Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs. Clin Exp Metastasis (2010) 0.79
Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responses. Mol Ther (2010) 0.78
Drug delivery strategies to control macrophages for tissue repair and regeneration. Exp Biol Med (Maywood) (2016) 0.77
Immunomodulation by topical particle-mediated administration of cytokine plasmid DNA suppresses herpetic stromal keratitis without impairment of antiviral defense. Graefes Arch Clin Exp Ophthalmol (2005) 0.77
The IL-1RN and IL-4 gene polymorphisms are potential genetic markers of susceptibility to bladder cancer: a case-control study. World J Urol (2014) 0.76
Association between polymorphisms in selected inflammatory response genes and the risk of prostate cancer. Onco Targets Ther (2016) 0.76
Comparison of the antiangiogenic activity of modified RGDRGD-endostatin to endostatin delivered by gene transfer in vivo rabbit neovascularization model. Mol Vis (2011) 0.76
Impact of single nucleotide polymorphism in IL-4, IL-4R genes and systemic concentration of IL-4 on the incidence of glioma in Iraqi patients. Int J Med Sci (2014) 0.76
The Production IL-21 and VEGF in UVB-irradiated Human Keratinocyte Cell Line, HaCaT. Immune Netw (2010) 0.75
Gallium maltolate inhibits human cutaneous T-cell lymphoma tumor development in mice. J Invest Dermatol (2014) 0.75
Dendritic Cell Regulation by Cannabinoid-Based Drugs. Pharmaceuticals (Basel) (2010) 0.75
Interleukin 4, interleukin 6 and osteopontin-serological markers of head and neck malignancy in primary diagnostics: A pilot study. Oncol Lett (2014) 0.75
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 13.94
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 13.76
Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1. Nature (1985) 11.55
Generation and analysis of interleukin-4 deficient mice. Science (1991) 8.80
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 7.66
Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature (1993) 6.54
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (1994) 5.54
A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A (1990) 5.26
Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1. Proc Natl Acad Sci U S A (1986) 4.69
An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science (1992) 3.78
Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell (1986) 3.70
Interleukin-4: a prototypic immunoregulatory lymphokine. Blood (1991) 3.64
CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol (1997) 3.52
A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci (1996) 3.49
Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell (1989) 3.43
Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol (1993) 3.15
Receptors for B-cell stimulatory factor-1 expressed on cells of haematopoietic lineage. Nature (1987) 2.94
Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (1991) 2.81
How tumors become angiogenic. Adv Cancer Res (1996) 2.63
The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol (1996) 2.50
Regulation of vascular cell adhesion molecule 1 on human dermal microvascular endothelial cells. J Immunol (1992) 1.96
Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cells. J Immunol (1996) 1.84
Heterogeneity of dermal microvascular endothelial cell antigen expression and cytokine responsiveness in situ and in cell culture. J Immunol (1993) 1.78
cDNA cloning and characterization of the human interleukin 13 receptor alpha chain. J Biol Chem (1996) 1.68
A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci U S A (1998) 1.66
Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4). J Immunol (1987) 1.48
Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum (1996) 1.35
Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res (1992) 1.34
Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res (1996) 1.33
Assay and purification of naturally occurring inhibitor of angiogenesis. Methods Enzymol (1991) 1.31
Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest (1993) 1.30
Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis. J Immunol (1993) 1.23
IL-4 and IL-13 activate the JAK2 tyrosine kinase and Stat6 in cultured human vascular endothelial cells through a common pathway that does not involve the gamma c chain. J Clin Invest (1996) 1.14
Interleukin-4 is a potent mitogen for capillary endothelium. Biochem Biophys Res Commun (1991) 1.10
Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat Genet (1995) 1.09
Two competing influences that may explain concomitant tumor resistance. Cancer Res (1993) 1.06
A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res (1997) 1.04
Biological activity of IL-4 and IL-13 on human endothelial cells: functional evidence that both cytokines act through the same receptor. Int Immunol (1996) 1.04
Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res (1995) 0.99
The paracrine role of tumour-derived mIL-4 on tumour-associated endothelium. Int J Cancer (1997) 0.94
In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant. J Cancer Res Clin Oncol (1994) 0.88
Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Expression of allograft endothelial VCAM-1 can be manipulated with antagonist of IFN-alpha or IL-4 and is not required for allograft rejection. Am J Pathol (1995) 0.87
The eosinophil-mediated antitumor activity of interleukin-4. J Allergy Clin Immunol (1994) 0.87
Interleukin-4 and cancer therapy. Cancer Invest (1993) 0.87
Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma model. Cell Immunol (1995) 0.87
Suppression of tumor growth with recombinant murine angiostatin. Biochem Biophys Res Commun (1997) 0.86
An interleukin (IL)-13 receptor lacking the cytoplasmic domain fails to transduce IL-13-induced signals and inhibits responses to IL-4. J Biol Chem (1997) 0.85
Tumor necrosis factor alpha enhances the expression of the interleukin (IL)-4 receptor alpha-chain on endothelial cells increasing IL-4 or IL-13-induced Stat6 activation. J Biol Chem (1997) 0.84
Interleukin 4 retards dissemination of a human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res (1995) 0.84
TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy. Eur J Cancer (1996) 0.80
The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature (1997) 34.00
Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science (2001) 21.99
DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae. Nature (2000) 19.93
Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science (2000) 16.04
Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature (1999) 14.42
The complete genome sequence of the hyperthermophilic, sulphate-reducing archaeon Archaeoglobus fulgidus. Nature (1997) 14.38
Identification and expression cloning of a leptin receptor, OB-R. Cell (1995) 9.74
Genome sequence of the radioresistant bacterium Deinococcus radiodurans R1. Science (1999) 8.01
Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell (1996) 7.45
The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest (1998) 6.51
Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science (1999) 5.53
A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A (1990) 5.26
CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol (1997) 3.52
Reversal of the antimicrobial activity of trimethoprim by thymidine in commercially prepared media. Appl Microbiol (1971) 3.38
Proteolytic processing in the biosynthesis of insulin and other proteins. Fed Proc (1974) 3.27
Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol (1998) 3.05
Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res (1998) 2.43
Genetic control of specific immune suppression. IV. Responsiveness to the random copolymer L-glutamic acid50-L-tyrosine50 induced in BALB/c mice by cyclophosphamide. J Exp Med (1976) 2.39
Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci U S A (1998) 2.35
Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell (1989) 2.27
Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest (1996) 2.24
T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. J Immunol (1997) 2.18
Immunosuppressive factor(s) specific for L-glutamic acid50-L-tyrosine50 (GT) II. Presence of I-J determinants on the GT-suppressive factor. J Exp Med (1977) 2.12
Immunosuppressive factor(s) specific for L-glutamic acid50-L-tyrosine50 (GT). III. Generation of suppressor T cells by a suppressive extract derived from GT-primed lymphoid cells. J Exp Med (1977) 2.08
Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol (1992) 2.08
Evidence of IL-18 as a novel angiogenic mediator. J Immunol (2001) 1.93
Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. Urology (2000) 1.92
Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum (2001) 1.91
Studies on the conversion of proinsulin to insulin. I. Conversion in vitro with trypsin and carboxypeptidase B. J Biol Chem (1971) 1.88
Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum (2001) 1.87
Adhesion molecule expression in human synovial tissue. Arthritis Rheum (1993) 1.79
Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exp Med (1993) 1.76
Stimulation of neovascularization by human rheumatoid synovial tissue macrophages. Arthritis Rheum (1986) 1.71
A non-contact mouse for surgeon-computer interaction. Technol Health Care (2004) 1.67
A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci U S A (1998) 1.66
Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism. Proc Natl Acad Sci U S A (1994) 1.65
Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci U S A (2000) 1.64
Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum (1994) 1.64
Determination of the amino acid sequence of the monkey, sheep, and dog proinsulin C-peptides by a semi-micro Edman degradation procedure. J Biol Chem (1972) 1.62
Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum (1996) 1.60
Genetic control of specific immune suppression. III. Mapping of H-2 complex complementing genes controlling immune suppression by the random copolymer L-glutamic acid50-L-tyrosine50 (GT). J Exp Med (1976) 1.57
Thrombospondin 1 synthesis and function in wound repair. Am J Pathol (1996) 1.52
Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum (2001) 1.49
Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc Natl Acad Sci U S A (1997) 1.47
The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1. J Lab Clin Med (1994) 1.44
Isolation and characterization of proinsulin C-peptide from bovine pancreas. J Biol Chem (1971) 1.41
Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol (1999) 1.37
Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol (2001) 1.36
Idiotypic analysis of monoclonal antibodies to poly(Glu60Ala30Tyr10). Proc Natl Acad Sci U S A (1979) 1.35
Fine specificity of antibodies to poly(Glu60Ala30Tyr10) produced by hybrid cell lines. Proc Natl Acad Sci U S A (1979) 1.32
Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum (2000) 1.31
IL-1beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis. J Urol (2000) 1.31
Assay and purification of naturally occurring inhibitor of angiogenesis. Methods Enzymol (1991) 1.31
Determinants of antigenic molecules responsible for genetically controlled regulation of immune responses. Proc Natl Acad Sci U S A (1976) 1.30
Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate (2001) 1.29
Regulation of immune responses by I-J gene products. I. Production and characterization of anti-I-J monoclonal antibodies. J Exp Med (1981) 1.25
A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biol Chem (2001) 1.23
Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res (1996) 1.23
IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J Immunol (2001) 1.21
Molecular mediators of angiogenesis in bladder cancer. Cancer Res (1998) 1.20
Chemokines and angiogenesis. Curr Opin Rheumatol (2001) 1.20
The structure of bovine proinsulin. J Biol Chem (1971) 1.20
The role of an epithelial neutrophil-activating peptide-78-like protein in rat adjuvant-induced arthritis. J Immunol (1999) 1.18
Cellular components and features of immune response in abdominal aortic aneurysms. Ann N Y Acad Sci (1996) 1.17
Bcl-2 expression in synovial fibroblasts is essential for maintaining mitochondrial homeostasis and cell viability. J Immunol (2000) 1.17
Human atherosclerotic abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-gamma but not IL-2 and IL-4: the possible role for IL-6 and interferon-gamma in vascular inflammation. Agents Actions (1994) 1.15
RANTES expression and contribution to monocyte chemotaxis in arthritis. Clin Immunol Immunopathol (1998) 1.13
Chemokines in rheumatoid arthritis. Springer Semin Immunopathol (1998) 1.12
Humoral immune functions in IL-4 transgenic mice. J Immunol (1991) 1.11
Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NFkappaB activation. Lab Invest (2001) 1.11
Rheumatoid arthritis synovial macrophages express the Fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein and are refractory to Fas-mediated apoptosis. Arthritis Rheum (2001) 1.11
Induction of neovascularization by activated human monocytes. J Leukoc Biol (1986) 1.09
Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat Genet (1995) 1.09
Inhibition of Theiler's virus-mediated demyelination by peripheral immune tolerance induction. J Immunol (1995) 1.09
Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. III. Failure of neuroantigen-specific immune tolerance to affect the clinical course of demyelination. J Neuroimmunol (1990) 1.06
Angiogenesis in rheumatoid arthritis: pathogenic and clinical significance. J Investig Med (1998) 1.06
Interleukin-1 beta and tumor necrosis factor-alpha release in normal and diseased human infrarenal aortas. J Vasc Surg (1992) 1.06
Interleukin-8 and tumor necrosis factor-alpha are involved in human aortic endothelial cell migration. The possible role of these cytokines in human aortic aneurysmal blood vessel growth. Pathobiology (1994) 1.05
Update on synovitis. Curr Rheumatol Rep (2001) 1.05
Immunosuppressive factor(s) specific for L-glutamic acid50-L-tyrosine50 (GT). I. Production, characterization, and lack of H-2 restriction for activity in recipient strain. J Immunol (1977) 1.04
Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum Gene Ther (1994) 1.03
Anergy in vivo: down-regulation of antigen-specific CD4+ Th1 but not Th2 cytokine responses. Int Immunol (1994) 1.03
Expression of functional B7 and CTLA4 on rheumatoid synovial T cells. J Immunol (1994) 1.02
Substance P (NK1)- and neurokinin A (NK2)-receptor gene expression in inflammatory airway diseases. Am J Physiol (1995) 1.01
Ley/H: an endothelial-selective, cytokine-inducible, angiogenic mediator. J Immunol (2000) 1.01
Keratinocyte growth factor induces angiogenesis and protects endothelial barrier function. J Cell Sci (1999) 0.99
Chronic lupus peritonitis with ascites: review of the literature with a case report. Semin Arthritis Rheum (1988) 0.98
Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest (2001) 0.98
Studies on human proinsulin. Isolation and amino acid sequence of the human pancreatic C-peptide. J Biol Chem (1971) 0.98
Increased synovial expression of transforming growth factor (TGF)-beta receptor endoglin and TGF-beta 1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol (1995) 0.98
Immunosuppressive factor(s) specific for L-glutamic acid50-L-tyosine50. IV. In vitro activity and immunochemical properties. Eur J Immunol (1977) 0.98
The amino acid sequence of the insulin from a primitive vertebrate, the atlantic hagfish (Myxine glutinosa). J Biol Chem (1975) 0.98
Unidirectional crosstalk between Bcl-xL and Bcl-2 enhances the angiogenic phenotype of endothelial cells. Cell Death Differ (2007) 0.97
Chemokine and chemokine receptor blockade in arthritis, a prototype of immune-mediated inflammatory diseases. Neth J Med (2011) 0.97
Regulation of immune responses by I-J gene products. III. GT-specific suppressor factor is composed of separate I-J and idiotype-bearing chains. J Immunol (1983) 0.96